Latest from The Angeles Clinic

Omid Hamid, MD, director of Research and Immuno-Oncology at The Angeles Clinic, discusses the inclusion of patients with brain metastases on melanoma clinical trials.
 
Omid Hamid, MD, director of Research and Immuno-Oncology at The Angeles Clinic, discusses the effectiveness of immunotherapy in adolescent and young adult (AYA) patients with melanoma. 
 
Omid Hamid, MD, director of Research and Immuno-Oncology at The Angeles Clinic, discusses a retrospective analysis of pembrolizumab (Keytruda) in patients with melanoma.
 
Ani Balmanoukian, MD, director of Thoracic Oncology, associate director of the Phase I Immune-Oncology Program, The Angeles Clinic and Research Institute, discusses immunotherapy advancements in genitourinary cancers.
Morganna Freeman, DO, associate director, Melanoma and Cutaneous Oncology Program, The Angeles Clinic and Research Institute, discusses the challenges associated with treatment selection in melanoma.
Omid A. Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses how to accurately select patients who are likely to have durable and long responses with single-agent immunotherapy versus combination treatment.
Omid Hamid, MD, Chief, Translational Research and Immunotherapy, Director, Melanoma Therapeutics, The Angeles Clinic, discusses a recent trial investigating the combination of vemurafenib and atezolizumab in melanoma in patients with previously untreated BRAF-positive unresectable or metastatic melanoma.
Omid Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses the possibility of using biomarkers to select immunotherapy as a treatment option for patients with melanoma.
Publication Bottom Border
Border Publication
x